Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials
Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing to fund the advancement of an investigational off-the-shelf neoantigen-based cancer immunotherapy. The round was co-led by M Ventures and Revelation Partners alongside new investors…
We haven't written up this one. EU-Startups has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Nouscom raises $135M in Series D for lead cancer vaccine endpoints.news